Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17351568 | 0.98 | DPP4 (0.39) | DPP4CYP4F2CYP4A11MEN1ALDH1A1 | |
| SCHEMBL17351421 | 0.96 | DPP4 (0.37) | DPP4CYP4F2CYP4A11MEN1ALDH1A1 | |
| SCHEMBL17351566 | 0.83 | DPP4 (0.43) | DPP4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL9713149 | 0.78 | CETP (0.36) | DPP4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1143121 | 0.77 | CYP4F2 (0.37) | DPP4CYP4F2CYP4A11 | |
| SCHEMBL1143119 | 0.76 | CYP2C19 (0.36) | DPP4CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL15571853 | 0.75 | CYP2C19 (0.33) | MCL1HSD17B10 | |
| SCHEMBL17351452 | 0.75 | NLRP3 (0.32) | MCL1HSD17B10 | |
| SCHEMBL17351358 | 0.74 | HSD17B10 (0.36) | DPP4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1142644 | 0.74 | CYP4F2 (0.35) | DPP4CYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2888245-B1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2888245-B1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | CACNA1E, CHRM1, CHRM2 | DPP4 2966/4885CYP4F2 2310/4885CYP4A11 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.